Welcome to our dedicated page for Endra Life Sciences SEC filings (Ticker: NDRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ENDRA Life Sciences Inc. (NDRA) SEC filings page provides direct access to the company’s regulatory disclosures, including Forms 10‑K, 10‑Q, 8‑K, registration statements and proxy materials. These documents explain how ENDRA is developing its Thermo Acoustic Enhanced UltraSound (TAEUS®) platform for liver fat measurement and other thermoacoustic applications, and how it manages capital and risk as a Nasdaq‑listed issuer in the electromedical and electrotherapeutic apparatus manufacturing industry.
Through annual and quarterly reports, investors can review detailed discussions of ENDRA’s business strategy, risk factors, research and development priorities, and its focus on steatotic liver disease (SLD), metabolic dysfunction‑associated steatohepatitis (MASH) and GLP‑1 therapy management. Current reports on Form 8‑K describe material events such as private placements with warrants, at‑the‑market (ATM) equity agreements, the launch of a digital asset treasury (DAT) strategy, and the engagement of Arca Investment Management and Anchorage Digital Bank to manage and custody cryptocurrency holdings.
Filings also document corporate governance and capital structure decisions, including amendments to the certificate of incorporation to increase authorized common shares, updates to the 2016 Omnibus Incentive Plan, and Nasdaq listing compliance matters related to stockholders’ equity. Registration statements on Form S‑1/A outline proposed offerings, use of proceeds for TAEUS development and DAT activities, and extensive risk factor sections addressing both medical device and digital asset considerations.
On Stock Titan, these filings are paired with AI‑powered summaries that highlight key points from lengthy documents, helping users quickly understand complex topics such as De Novo regulatory plans for TAEUS Liver, equity financing terms, warrant structures and DAT‑related risk disclosures. Investors can also monitor insider‑related information through ownership tables and compensation discussions included in proxy statements and periodic reports.
ENDRA Life Sciences reported that Chief Executive Officer Alexander Y. Tokman acquired 26,921 shares of common stock through a grant of restricted stock units (RSUs) at a price of $0.00 per share. These RSUs convert to common stock on a one-for-one basis and will vest in full on June 11, 2026. Following this award, Tokman directly holds 101,926 shares of common stock, and the holdings disclosure notes that this amount includes unvested RSUs.
ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, received a grant of 13,461 shares of common stock as a stock award. The shares, structured as restricted stock units that convert one-for-one into common stock, will vest in full on June 11, 2026. Following this award, Jacroux holds 33,461 shares of common stock, including unvested restricted stock units.
ENDRA Life Sciences Inc. director Anthony DiGiandomenico reported a stock-based award of the company’s common stock. On January 21, 2026, he acquired 60,324 shares at a price of $0, representing restricted stock units (RSUs) that convert to common stock on a one-for-one basis. These RSUs will vest in full on January 21, 2027, meaning he will receive the underlying shares on that date if vesting conditions are met. After this grant, he beneficially owns 136,589 shares of ENDRA common stock, held directly, which includes unvested RSUs.
ENDRA Life Sciences director Michael Harsh reported an equity award of 60,324 shares on January 21, 2026. The filing shows these are restricted stock units (RSUs) that convert into common stock on a one-for-one basis and will vest in full on January 21, 2026. The transaction was recorded at a price of $0 per share, indicating a compensatory grant rather than an open-market purchase. Following this award, Harsh beneficially owned 65,710 shares of common stock, and his holdings include unvested RSUs.
ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, acquired 20,000 shares of common stock on January 21, 2026. The shares come from restricted stock units that were granted at a price of $0 per share and convert into common stock on a one-for-one basis. After this transaction, he beneficially owns 20,000 common shares directly. The RSUs are scheduled to vest in full on January 21, 2027, meaning the CFO will receive all underlying shares on that date if vesting conditions are met.
ENDRA Life Sciences director Lou Basenese received a stock-based award from the company. On January 21, 2026, he was granted 60,324 shares of common stock in the form of restricted stock units (RSUs) at a grant price of $0 per share. Each RSU converts into one share of common stock.
The RSUs will vest in full on January 21, 2027, meaning they convert to common shares on that date if vesting conditions are met. After this grant, Basenese beneficially owned a total of 65,709 shares of ENDRA Life Sciences common stock, which the disclosure notes includes unvested RSUs, all held directly.
ENDRA Life Sciences Chief Executive Officer and Director Alexander Y. Tokman received 75,000 shares of common stock on January 21, 2026 as an equity award. These shares represent restricted stock units that convert into common stock on a one-for-one basis and will vest in full on January 21, 2027. Following this grant, Tokman beneficially owned 75,005 shares of ENDRA Life Sciences common stock directly.
ENDRA Life Sciences Inc. reported results of its 2025 annual stockholder meeting. Stockholders approved a Certificate of Amendment to increase the authorized shares of common stock from 20,000,000 to 1,000,000,000, with the change becoming effective upon filing with the Delaware Secretary of State on December 10, 2025.
Stockholders also approved a Second Amendment to the company’s 2016 Omnibus Incentive Plan and re-elected four directors to serve until the next annual meeting. They ratified RBSM LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025 and approved executive compensation on an advisory basis, while a proposal to add officer exculpation to the certificate of incorporation did not receive sufficient support.
ENDRA Life Sciences Inc. is registering the resale by existing investors of up to 2,677,680 shares of common stock, including PIPE shares and shares underlying several series of warrants. The company itself is not selling stock in this prospectus and will only receive cash if holders exercise warrants.
The filing also outlines a new digital asset treasury strategy under which ENDRA plans to hold a majority of its treasury reserves in one to five decentralized finance cryptocurrencies, beginning with the HYPE token, and may use proceeds of future financings to buy additional cryptocurrency. As of this prospectus, ENDRA holds approximately 78,863.1 HYPE tokens and expects its share price and reported earnings to be influenced by volatile crypto prices and evolving accounting rules.
ENDRA continues to develop its TAEUS ultrasound platform for liver fat measurement and intends to use a portion of recent private placement proceeds to fund a pilot validation study of its TAEUS liver device while most of those proceeds support the new crypto-focused treasury strategy.
ENDRA Life Sciences (NDRA) updated its Nasdaq compliance status. The company reported a private placement closed on October 15, 2025, issuing 744,340 shares (or prefunded warrants in lieu) and warrants for up to 1,488,680 shares with exercise prices of $6.32 (and $6.81 for a director), generating approximately $4.9 million in gross proceeds. On October 29, 2025, it also entered an at-the-market program with Lucid Capital Markets for up to $1,750,000 in aggregate gross proceeds.
The company purchased 78,863.1 HYPE tokens as part of a digital asset treasury strategy. Based on these actions, ENDRA believes it has regained compliance with Nasdaq’s minimum $2.5 million stockholders’ equity requirement. Nasdaq will continue to monitor compliance and may delist the company if a future periodic report does not evidence compliance.